MOGAMULIZUMAB
mogamulizumab 20 mg/5 mL injection, 5 mL vial
MOGAMULIZUMAB (15277C)
15277C
Manner of administration:Injection
Restriction
Indication: Cutaneous T-cell lymphoma
Treatment phase: Continuing treatment
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 120 mg | # of repeats: 7 | DPMA: $13,418.26 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| POTELIGEO
(mogamulizumab 20 mg/5 mL injection, 5 mL vial)
|
||||
